Power Law company profile

Karyopharm Therapeutics

Biotech & Life Sciences · Newton, United States · Founded 2008 · IPO 2013 Thoroughbred

Karyopharm Therapeutics Inc. is an oncology-focused biopharmaceutical company focused on the discovery, development and commercialization of novel medicines

Valuation

$357M

Market cap · May/2026

Revenue

$145M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

4 investors on Karyopharm Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 4 investors entered at this stage

Delphi Ventures

Foresite Capital

RA Capital Management

Adage Capital

Global footprint

Where Karyopharm Therapeutics has talent and traffic

AI talent share

1.3% of workforce is AI talent
(4 of 313 staff)

Core AI00%

Other AI41.28%

Non-AI workforce30998.72%

Workforce by country

🇺🇸 United States · Newton HQ

Book a demo for the full country breakdown

Web traffic by country

8.9K monthly visits
across markets

🇺🇸 United States67.4%

🇨🇦 Canada11.2%

🇮🇳 India10.1%

🇬🇧 United Kingdom10.1%

Top 4 markets shown

Market sentiment

What the market is saying about Karyopharm Therapeutics

An AI-synthesized read of the highest-engagement posts about Karyopharm Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Karyopharm Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles